Mary Beth Nierengarten is a freelance medical journalist based in Minneapolis.
References
- Merrill JT, Wallace DJ, Wax S, et al. Efficacy and safety of atacicept in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2018 Feb;70(2):266–276.
- Dall’Era M, Chakravarty E, Wallace D, et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: Results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum. 2007 Dec;56(12):4142–4150.
- Pena-Rossi C, Nasonov E, Stanislav M, et al. An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus. 2009 May;18(6):547–555.